MX2018016279A - Compuestos para formacion de imagenes de agregados de proteinas tau. - Google Patents

Compuestos para formacion de imagenes de agregados de proteinas tau.

Info

Publication number
MX2018016279A
MX2018016279A MX2018016279A MX2018016279A MX2018016279A MX 2018016279 A MX2018016279 A MX 2018016279A MX 2018016279 A MX2018016279 A MX 2018016279A MX 2018016279 A MX2018016279 A MX 2018016279A MX 2018016279 A MX2018016279 A MX 2018016279A
Authority
MX
Mexico
Prior art keywords
compounds
tau protein
protein aggregates
imaging tau
imaging
Prior art date
Application number
MX2018016279A
Other languages
English (en)
Inventor
Kroth Heiko
Berndt Mathias
Müller Andre
Schmitt-Willich Heribert
Oden Felix
Molette Jérôme
Gabellieri Emanuele
Darmency Vincent
Schieferstein Hanno
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of MX2018016279A publication Critical patent/MX2018016279A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención se refiere a compuestos novedosos de la fórmula (II) que pueden emplearse en la detección selectiva de Tau de trastornos y anomalías asociadas con agregados de Tau, como la enfermedad de Alzheimer y otras tauopatías, usando la formación de imágenes de tomografía por emisión de positrones (PET).
MX2018016279A 2016-07-22 2017-07-21 Compuestos para formacion de imagenes de agregados de proteinas tau. MX2018016279A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16180908 2016-07-22
PCT/EP2017/068509 WO2018015549A1 (en) 2016-07-22 2017-07-21 Compounds for imaging tau protein aggregates

Publications (1)

Publication Number Publication Date
MX2018016279A true MX2018016279A (es) 2019-09-06

Family

ID=56550098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016279A MX2018016279A (es) 2016-07-22 2017-07-21 Compuestos para formacion de imagenes de agregados de proteinas tau.

Country Status (13)

Country Link
US (1) US10835624B2 (es)
EP (1) EP3487544A1 (es)
JP (1) JP7197476B2 (es)
KR (1) KR102472003B1 (es)
CN (2) CN109475648B (es)
AU (1) AU2017299219B2 (es)
BR (1) BR112019000946A8 (es)
CA (1) CA3030511A1 (es)
IL (2) IL264239B (es)
MX (1) MX2018016279A (es)
MY (1) MY196981A (es)
SG (1) SG11201811311VA (es)
WO (1) WO2018015549A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3487545A1 (en) * 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
CA3088232A1 (en) * 2018-01-24 2019-08-01 Ac Immune Sa Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics
WO2019145291A1 (en) * 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
BR112020014949A8 (pt) * 2018-01-24 2022-12-13 Ac Immune Sa Método de preparação de um composto de formação de imagem
KR102594570B1 (ko) * 2020-11-12 2023-10-26 사회복지법인 삼성생명공익재단 질소를 함유하는 헤테로아렌 화합물 기반 방사성 리간드 및/또는 비방사성 리간드의 합성 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2247558T (lt) 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012067863A1 (en) 2010-11-16 2012-05-24 Ge Healthcare Limited Heterocyclic compounds as imaging probes of tau pathology
JP2013542993A (ja) 2010-11-19 2013-11-28 ジーイー・ヘルスケア・リミテッド 初期タウオパシーの診断のためのチウの検出におけるシアニン色素の使用
CN104781234A (zh) 2012-05-22 2015-07-15 伊莱利利公司 用于检测神经功能障碍的基于咔啉和咔唑的成像剂
RU2015106437A (ru) 2012-08-14 2016-10-10 Ф.Хоффманн-Ля Рош Аг Производные имидазо[2,1]тиазол-3-она, пригодные в качестве диагностических агентов для болезни альцгеймера
KR20160003173A (ko) 2013-04-29 2016-01-08 에프. 호프만-라 로슈 아게 2-페닐 또는 2-헤트아릴 이미다졸[1,2-a]피리딘 유도체
SI2999701T1 (sl) 2013-05-23 2017-08-31 F. Hoffmann-La Roche Ag 2-fenilimidazo(1,2-a)pirimidini kot sredstva za slikanje
US20160115162A1 (en) 2013-05-31 2016-04-28 The General Hospital Corporation Radiosynthesis of Tau Radiopharmaceuticals
MX2016003422A (es) 2013-09-26 2016-06-28 Hoffmann La Roche Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
LT3055308T (lt) * 2013-10-08 2018-02-12 F. Hoffmann-La Roche Ag Diazakarbazolo dariniai kaip taupet ligandai
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
HUE053939T2 (hu) 2014-05-13 2021-08-30 Hoffmann La Roche Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
KR102409017B1 (ko) 2014-10-08 2022-06-16 텍사스 칠드런스 하스피탈 리포좀을 이용한 아밀로이드 플라크의 mri 영상화
JP6579670B2 (ja) * 2015-02-02 2019-09-25 ユーシービー バイオファルマ エスピーアールエル ９ｈ−ピロロ−ジピリジン誘導体
WO2016140243A1 (ja) 2015-03-02 2016-09-09 国立研究開発法人理化学研究所 高分子化合物及び高分子化合物の製造方法

Also Published As

Publication number Publication date
IL264239B (en) 2022-08-01
CN115650982A (zh) 2023-01-31
RU2019104415A (ru) 2020-08-24
US20190262480A1 (en) 2019-08-29
JP2019523298A (ja) 2019-08-22
IL295000B1 (en) 2023-04-01
AU2017299219A1 (en) 2019-01-17
WO2018015549A1 (en) 2018-01-25
CN109475648A (zh) 2019-03-15
JP7197476B2 (ja) 2022-12-27
SG11201811311VA (en) 2019-01-30
KR102472003B1 (ko) 2022-11-29
CN109475648B (zh) 2023-03-14
AU2017299219B2 (en) 2022-12-22
IL264239A (en) 2019-02-28
BR112019000946A8 (pt) 2022-12-13
IL295000B2 (en) 2023-08-01
KR20190031312A (ko) 2019-03-25
BR112019000946A2 (pt) 2019-04-30
RU2019104415A3 (es) 2020-11-26
US10835624B2 (en) 2020-11-17
MY196981A (en) 2023-05-16
IL295000A (en) 2022-09-01
EP3487544A1 (en) 2019-05-29
CA3030511A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
MX2018016279A (es) Compuestos para formacion de imagenes de agregados de proteinas tau.
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
MX2017006785A (es) Metodos y composiciones para radioetiquetado con 18f de productos biologicos.
EA201791733A1 (ru) Производные 9h-пирролодипиридина
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
MX356800B (es) Anticuerpo tau humanizado.
PH12017500032A1 (en) Improved a� protofibril binding antibodies
MX2020010847A (es) Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.
EA201691529A1 (ru) Гетероарильные амиды в качестве ингибиторов агрегации белков
PH12018500578A1 (en) Methods of treating inflammatory diseases
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
MX2017011598A (es) Metodos para tratar proteinopatias.
ZA201804079B (en) Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease, or in the diagnosis of parkinson's disease
WO2014160871A3 (en) Methods and agents for treating alzheimer's disease
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX2020007487A (es) Composiciones de diagnostico para produccion de imagenes de tomografia por emision de positrones, metodo para fabricar la composicion de diagnostico y su uso en diagnostico.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2020007298A (es) Nuevo metodo para preparar compuesto para formacion de imagenes.
RU2014138694A (ru) Состав для стимуляции метаболических процессов, системы иммунитета, профилактики заболеваний диареей
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
MX2017009452A (es) Agentes de imagenologia para tomografia de emision de positrones (pet).
EA201790117A1 (ru) Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение
PL409386A1 (pl) Preparaty peptydowe do zastosowania jako środek farmaceutyczny lub dodatek do żywności w zapobieganiu i leczeniu chorób neurodegeneracyjnych
TH161632B (th) รถแทรกเตอร์